Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Cracking the Code to Society’s Most Feared Disease

Even more so than cancer, it’s the one disease that we all fear the most. The thought of falling prey to Alzheimer’s disease and to the inevitable desecration of our mind is something that makes even the bravest among us shudder. ...
Marc Davis | February 7, 2020 |

A ‘Barrier’ to Better Health

(Click image to play podcast) The blood-brain barrier plays an essential role in protecting the brain from blood-borne disease. But is also one of medicine’s great paradoxes – a system designed to protect the most sensitive region of the body bu...
Dave Jackson | September 29, 2020 |

Covid 19: Will pain-free, at-home screening tests be our salvation?

The world’s best defence against the spread of COVID-19 in 2021 will not be a vaccine, medical experts now say. Instead, it will be the widespread adoption of cheap, non-invasive diagnostic detection devices for coronaviruses – ones that look and function...
Marc Davis | September 1, 2020 |

InMed Shares Trade Up 25% After Becoming First to Advance Cannabinol into Clinical Trials

InMed Pharmaceuticals shares traded 25% higher after reporting that it is the first to advance cannabinol into therapeutic clinical trials. Vancouver-based clinical stage biopharmaceutical company InMed Pharmaceuticals Inc. (IN:TSX; IMLFF:OTCQX) , which is engaged in...
Streetwise Reports | January 21, 2020 |

A Topical Solution for Chronic Pain

Pain impedes the life of millions around the world, and the market for topical creams to treat this pain is growing at an accelerated rate as people choose to treat pain directly vs ingesting pain killers. Some analysts, such as those at Allied Market Research, project that ...
Jonathon Brown | May 2, 2022 |

NervGen: Are amazing human trial results leaking out?

“We are very excited! We are very, very excited!” So says Dr. Monica Perez, who is running the first human trial for a potential new wonder drug being developed by a tiny but well-financed life sciences start-up, NervGen Pharma Corp. ...
Knox Henderson | July 2, 2024 |

Baudax Shares Rise as FDA Approves NDA for Its Non-Opioid Pain Medication

Shares of Baudax Bio traded more than 20% higher and set a new 52-week high price after reporting that the FDA approved the company's non-opioid ANJESO™ drug for management of moderate to severe pain. Specialty pharmaceutical company Baudax Bio Inc. (BXRX:N...
Streetwise Reports | February 24, 2020 |

FDA Approval of Biopharma's Pain Drug Expected This Year

The reasons a green light is anticipated and how it relates to the closing of Avenue Therapeutics' pending acquisition are discussed in an H.C. Wainwright & Co. report. In a Feb. 13 research note, H.C. Wainwright & Co. analyst Ed Arce reported that the U.S. ...
Streetwise Reports | February 20, 2020 |

Assertio Therapeutics' Shares Jump 50% on Sale of Shingles Pain Drug to Alvogen

Assertio Therapeutics' shares rose 50% today after the firm reported that it has agreed to sell all rights to its Gralise drug used in the treatment of pain from shingles to Alvogen for $127.5 million. The transaction is expected to close in January 2020. Shares of ph...
Streetwise Reports | December 13, 2019 |

NervGen Pharma: A “Blockbuster Drug” in the Making?

It has the potential to be one of the most disruptive pharmaceutical drug therapies of the modern era, especially for treating Alzheimer’s disease. And that gives it considerable “blockbuster drug” potential – a tantalising opportunity tha...
Marc Davis | June 25, 2021 |
1 2 3 4 5 6 7 8 9 10 ...